Tag: Executive Leadership

Vivos Inc. converts IDE submission to Pre-Sub filing with FDA approval, focusing on comprehensive review and risk/benefit analysis for Radiogel®

IsoPet® by Vivos Inc. (OTCQB: RDGL) uses Yttrium-90 for precise cancer treatment in animals. Learn about its technology, clinic expansion, and future plans.

Vivos Inc. advances with Reg A-1 filing to support human trials and expand animal therapies, reflecting growth potential and commitment to oncology innovation.

Vivos Inc. (RDGL) announces submission of IDE application to FDA for RadioGel™, advancing treatment for papillary thyroid cancer.

Dive into Vivos Inc.'s strategic advancements, from FDA breakthroughs in human cancer therapy to expanding IsoPet® services for pets.